Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Squamous Cell Carcinoma of Head and Neck 22Lung Neoplasms 22Oropharyngeal Neoplasms 14Nasopharyngeal Carcinoma 13Carcinoma 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 8Head and Neck Neoplasms 8Mouth Neoplasms 6Laryngeal Neoplasms 6Small Cell Lung Carcinoma 5Neoplasms 5Hypopharyngeal Neoplasms 5Cholangiocarcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lymphoid Interstitial Pneumonia 3Lung Diseases 3Carcinoma, Transitional Cell 3Carcinoma, Squamous Cell 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3

Interventions

durvalumab 2Tretinoin 2Paclitaxel 2Carboplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1talazoparib 1sarilumab 1pexidartinib 1pertuzumab 1pembrolizumab 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1dostarlimab 1cemiplimab 1abemaciclib 1Trastuzumab 1Standard of Care 1STA 9090 1SGN-LIV1A 1Pemetrexed 1MK 2206 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Cisplatin × 30 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡